Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue SUPPL. 95, 2011, Pages 41-43

  Jung, Kirsten ^a  

^a Clinic of Dermatology Erfurt   (Germany)

Author keywords

Optimised ratio; short updosing phase; subcutaneous immunotherapy; tolerability study

Indexed keywords

ALLERGEN; ALUMINUM HYDROXIDE; ALUTARD; ANTIALLERGIC AGENT; AVANZ; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G4; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; DRUG SAFETY; DRUG TOLERABILITY; EYELID EDEMA; GRASS POLLEN; HUMAN; NONHUMAN; PRIORITY JOURNAL; PRURITUS; RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; URTICARIA;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ALUMINUM HYDROXIDE; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MICE; POACEAE; POLLEN; TREATMENT OUTCOME;

EID: 79958787590     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02632.x     Document Type: Article

References (8)

1. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, et al., Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62: 943-948. (Pubitemid 47037870)
2. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F,. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56: 498-505. (Pubitemid 32521429)
3. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A,. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60: 801-807. (Pubitemid 40769884)
4. Fernandez-Rivas M, Brewczynski PZ, Kroon AM, van Ree R,. A clinical trial with purified natural major allergens from grass pollen. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 1999; 93: 131-136.
5. Lambrecht BN, Kool M, Willart MA, Hammad H,. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009; 21: 23-29.
6. Rask C, Lund L, Lund G, Urioste S, Thorup S, Bergmann K, et al., Optimised allergen: adjuvant ratio potentiates immunogenicity of AlOH-formulated Phleum pratense extract. Allergy 2010; 65 (Suppl. 2):175.
7. Wolf KJK, Schnitker J, Wuestenberg E,. Subcutaneous immunotherapy with preparation with optimised allergen aluminium hydroxide ratio: immunologic effects. Allergy 2010; 65 (Suppl. 2):134.
8. Jung KWH, Schnitker J, Wuestenberg E,. Subcutaneous immunotherapy with preparation with optimised allergen aluminium hydroxide ratio: a randomised parallel-group clinical trial investigating safety and tolerability. Allergy 2010; 65 (Suppl. 2):4.